Details for Patent: 7,968,543
✉ Email this page to a colleague
Which drugs does patent 7,968,543 protect, and when does it expire?
Patent 7,968,543 protects VANFLYTA and is included in one NDA.
This patent has twenty-two patent family members in seventeen countries.
Drugs Protected by US Patent 7,968,543
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 7,968,543 | ⤷ Subscribe | Y | COMBINATION WITH STANDARD CYTARABINE AND ANTHRACYCLINE INDUCTION AND CYTARABINE CONSOLIDATION, AND AS MAINTENANCE MONOTHERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA | ⤷ Subscribe | |||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-002 | Jul 20, 2023 | RX | Yes | Yes | 7,968,543 | ⤷ Subscribe | Y | COMBINATION WITH STANDARD CYTARABINE AND ANTHRACYCLINE INDUCTION AND CYTARABINE CONSOLIDATION, AND AS MAINTENANCE MONOTHERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,968,543
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 069244 | ⤷ Subscribe | |||
| Australia | 2008325141 | ⤷ Subscribe | |||
| Canada | 2696807 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
